Erasca, Inc (ERAS) releases slides on phase 1 data for RAS cancer drug ERAS-0015
Tweet Send to a Friend
Erasca, Inc (NASDAQ: ERAS) disclosed:On April 27, 2026, Erasca, Inc. (the “Company”) announced positive preliminary Phase 1 dose escalation data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
